Comparison of two drugs in patients with prediabetes and dyslipedemia.

Comparison of effect of Sarglitazar and Metformin in cases of metabolic syndrome - COSMET

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/04/018849

Enrollment

100

Registered

2019-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E669- Obesity, unspecified

Interventions

Intervention1: saroglitazar: tab saroglitazar 4 mg daily per oral for 1 year Control Intervention1: metformin: metformin 850 mg once a day per oral for 1 year

Eligibility

Inclusion criteria

Inclusion criteria: Impaired fasting glucose hypertriglyceridemia high blood pressue/ abdominal girth >102cm in males or >88 cm in females low HDL

Exclusion criteria

Exclusion criteria: diabetes/alcoholism/pregnancy/Chronic liver disease/chronic kidney disease/ coronary artery disease/hormonal treatment

Design outcomes

Primary

Measure	Time frame
blood glucose-( fasting and postprandial) level serum triglyceride levelTimepoint: 3, 6, 9 , and 12 months	—

Secondary

Measure	Time frame
weight reduction, patient satisfactionTimepoint: 3 month 6month 9 month 12 month	—

Countries

India

Contacts

Public Contactdivendu bhushan

AIIMS, Patna

divendub@gmail.com9661216010

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026